

# SMARTWEALTH DOLLAR EQUITY ALL CHINA FUND

## October 2019

**BLOOMBERG: AZUSWAC:IJ**

### Investment Objective

The objective of this fund is to achieve conservative long term capital growth while earning more relatively stable income.

### Investment Strategy

To achieve the investment objective, this fund shall be invested 0% - 20% in short-term instruments (such as time deposits and / or money market mutual funds), and 80% - 100% in offshore instruments (through mutual funds).

### Return Performance

Last 1-year Period		N/A
Best Month	Oct-19	3.97%
Worst Month	Oct-19	3.97%

### Portfolio Breakdown

Mutual Funds - Equities	94.30%
Cash/Deposit	5.70%

### Key Fund Facts


Fund Size (in mio USD)	USD 6.87
Risk Profile	Aggressive
Launch Date	02 Sep 2019
Fund Currency	United States Dollar
Pricing Frequency	Daily
Bid-Offer Spread	5.00%
Management Fee	2.00% p.a.

<b>Price per Unit</b>	<b>Bid</b>	<b>Offer</b>
(As of Oct 31, 2019)	USD 0.9994	USD 1.0520

Managed by Allianz Global Investor

	1 Month	3 Months	6 Months	1 Year	3 Years	YTD	Since Inception
Smartwealth Dollar Equity All China Fund	3.97%	N/A	N/A	N/A	N/A	N/A	5.20%
Benchmark*	3.69%	N/A	N/A	N/A	N/A	N/A	3.22%

\*MSCI China All Shares Index (M1CNAL Index)



### Manager Commentary

The portfolio outperformed the benchmark MSCI China All Shares Index in September. Alpha was mainly contributed by stock selection in Industrials and Information Technology; while stock selection in Health Care detracted. In terms of market and sector allocation, the portfolio typically stays close to the benchmark. Such disciplined portfolio construction ensures that alpha is always generated through stock selection rather than allocation.

Top contributor over the month was Jiangsu Hengli Hydraulics, China's largest hydraulic component producer. Share price reacted positively to improving outlook of construction machinery demand in China driven by easing government policies to support economic growth. Over the long term, we believe this company should continue to expand its product range and client segments and further raise its market share through replacing foreign brands.

On the other hand, one of the top detractors was a leading innovative drug developer in China, listed on Hong Kong Stock Exchange. Its share price reacted negatively to the intensive competition in the latest national tendering process, which may lead to weak earnings growth over the near future. Within the Health Care space, we are diversifying our positions towards areas that are relatively less impacted by the national tendering system, including those firms that specialise in drug discovery and clinical trial processes.

#### Disclaimer:

Smartwealth Dollar Equity All China Fund is unit linked fund offered by PT. Asuransi Allianz Life Indonesia (Allianz). This fact sheet is prepared by Allianz. The information presented is for informational use only. The performance of the fund is not guaranteed and the value of the units and the income from them may increase or decrease. Past returns and any forecast are not necessarily a guide to future performance. Allianz does not warrant or make any representations regarding the use or the results of the use of the figures generated in terms of their correctness, accuracy, reliability, or otherwise. You are advised to seek your financial consultant before making any investment.